Giant cell arteritis and innovative treatments.

Giulia Costanzo, Andrea Giovanni Ledda, Giada Sambugaro

Current opinion in allergy and clinical immunology 2023 Aug 01

filter terms:

Giant cell arteritis (GCA) is an idiopathic and persistent condition characterized by granulomatous vasculitis of the medium and large vessels with overlapping phenotypes, including conventional cranial arteritis and extra-cranial GCA, also known as large-vessel GCA. Vascular problems linked with large vessel involvement may partly be caused by delayed diagnosis, emphasizing the necessity of early detection and the fast beginning of appropriate therapy. Glucocorticoids are the cornerstone of treatment for GCA, but using them for an extended period has numerous, often severe, side effects. clinical practice and novel discoveries on the pathogenic pathways suggest that steroid-free biologic treatments may be efficient and safe for GCA patients. since now, only Tocilizumab is approved for GCA treatment, but several drugs are currently used, and ongoing trials could give both researchers and patients novel therapeutic strategies for induction, maintenance, and prevention of relapse of GCA. The aims of this work is to synthesize evidence from current studies present in scientific literature about innovative treatment of Giant cell artheritis. Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.

Citation

Giulia Costanzo, Andrea Giovanni Ledda, Giada Sambugaro. Giant cell arteritis and innovative treatments. Current opinion in allergy and clinical immunology. 2023 Aug 01;23(4):327-333